Literature DB >> 29247124

Response to: '2017 EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: little emphasis on autoantibodies, why?' by Malaviya.

Ingrid E Lundberg1, Anna Tjärnlund1.   

Abstract

Entities:  

Keywords:  autoantibodies; disease activity; inflammation

Mesh：

Substances：

Year:  2017        PMID： 29247124     DOI： 10.1136/annrheumdis-2017-212709

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  4 in total

1.  Positioning of myositis-specific and associated autoantibody (MSA/MAA) testing in disease criteria and routine diagnostic work-up.

Authors:  Carolien Bonroy; Yves Piette; Yves Allenbach; Xavier Bossuyt; Jan Damoiseaux
Journal:  J Transl Autoimmun       Date:  2022-02-11

2.  An Italian Multicenter Study on Anti-NXP2 Antibodies: Clinical and Serological Associations.

Authors:  Micaela Fredi; Ilaria Cavazzana; Angela Ceribelli; Lorenzo Cavagna; Simone Barsotti; Elena Bartoloni; Maurizio Benucci; Ludovico De Stefano; Andrea Doria; Giacomo Emmi; Martina Fabris; Marco Fornaro; Federica Furini; Maria Grazia Giudizi; Marcello Govoni; Anna Ghirardello; Luca Iaccarino; Fiorenzo Iannone; Maria Infantino; Natasa Isailovic; Maria Grazia Lazzaroni; Mariangela Manfredi; Alessandro Mathieu; Emiliano Marasco; Paola Migliorini; Carlomaurizio Montecucco; Boaz Palterer; Paola Parronchi; Matteo Piga; Federico Pratesi; Valeria Riccieri; Carlo Selmi; Marilina Tampoia; Alessandra Tripoli; Giovanni Zanframundo; Antonella Radice; Roberto Gerli; Franco Franceschini
Journal:  Clin Rev Allergy Immunol       Date:  2022-01-29       Impact factor: 10.817

Review 3.  Current Classification and Management of Inflammatory Myopathies.

Authors:  Jens Schmidt
Journal:  J Neuromuscul Dis       Date:  2018

4.  Including myositis-specific autoantibodies improves performance of the idiopathic inflammatory myopathies classification criteria.

Authors:  Fergus To; Matthew J S Parker; Clara Ventín-Rodríguez; James B Lilleker; Hector Chinoy
Journal:  Rheumatology (Oxford)       Date:  2019-12-01       Impact factor: 7.580
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.